Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · IEX Real-Time Price · USD
1.110
-0.040 (-3.48%)
Jul 19, 2024, 1:48 PM EDT - Market open

Virax Biolabs Group Balance Sheet

Millions USD. Fiscal year is Apr - Mar.
Year Ending
TTM Mar 31, 2023Mar 31, 2022Mar 31, 2021Mar 31, 2020
Cash & Equivalents
5.119.350.020.020.02
Cash & Cash Equivalents
5.119.350.020.020.02
Cash Growth
43646.85%42888.32%23.47%-22.06%-
Receivables
00000
Inventory
0.0200.020.020
Other Current Assets
0.840.280.0100
Total Current Assets
5.979.630.050.040.02
Property, Plant & Equipment
0.680000
Goodwill and Intangibles
0.370.18000
Total Long-Term Assets
1.050.18000
Total Assets
7.039.810.050.040.02
Accounts Payable
0.740.721.240.871.03
Deferred Revenue
00.04000
Current Debt
0.050.15000
Other Current Liabilities
00000.21
Total Current Liabilities
0.790.911.250.871.24
Long-Term Debt
0.130000
Total Long-Term Liabilities
0.130000
Total Liabilities
0.920.911.250.871.24
Total Debt
0.180.15000
Debt Growth
81.71%----
Retained Earnings
-14.8-11.79-6.34-4.63-3.98
Comprehensive Income
0.04-0-0-00
Shareholders' Equity
6.339.13-0.97-0.65-1.06
Net Cash / Debt
4.939.210.020.020.02
Net Cash / Debt Growth
-42216.09%23.47%-22.06%-
Net Cash Per Share
2.778.660.020.070.22
Working Capital
5.188.73-1.2-0.83-1.22
Book Value Per Share
3.578.59-1.02-2.71-10.12
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).